Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotics for Febrile Neutropenia in Stem Cell Transplant Recipients
NCT03078010Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2017
- Primary completion
- Feb 2027
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2 trial of cefepime in febrile neutropenia (FN) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Measurement of fold-change in Clostridiales abundance at 7 days. Started Feb 2017; status: active, not recruiting.
02
Drugs
cefepime
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT03078010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078010.